Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 1.14.19.17 extracted from

  • Jang, Y.; Rao, X.; Jiang, Q.
    Gamma-tocotrienol profoundly alters sphingolipids in cancer cells by inhibition of dihydroceramide desaturase and possibly activation of sphingolipid hydrolysis during prolonged treatment (2017), J. Nutr. Biochem., 46, 49-56 .
    View publication on PubMedView publication on EuropePMC

Inhibitors

Inhibitors Comment Organism Structure
gamma-tocotrienol a component of vitamin E, gammaTE, inhibits DEGS and decreases de novo ceramide synthesis, elevation of ceramides during prolonged gammaTE treatment is likely caused by sphingomeylinase-mediated hydrolysis of sphingomyelin Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens O15121
-
-

Source Tissue

Source Tissue Comment Organism Textmining
HCT-116 cell
-
Homo sapiens
-
MCF-7 cell
-
Homo sapiens
-
PANC-1 cell
-
Homo sapiens
-

Synonyms

Synonyms Comment Organism
DegS
-
Homo sapiens
dihydroceramide desaturase
-
Homo sapiens

Temperature Optimum [°C]

Temperature Optimum [°C] Temperature Optimum Maximum [°C] Comment Organism
37
-
assay at Homo sapiens

pH Optimum

pH Optimum Minimum pH Optimum Maximum Comment Organism
7.4
-
assay at Homo sapiens

General Information

General Information Comment Organism
malfunction gamma-tocotrienol inhibits cellular dihydroceramide desaturase (DEGS) activity without affecting its protein expression or de novo synthesis of sphingolipids. Unlike the effect on dihydroceramides, gamma-tocotrienol decreases ceramides (Cers) after 8-h treatment but increases C18:0-Cer and C16:0-Cer after 16 and 24 h, respectively. The increase of ceramides coincides with gamma-tocotrienol-induced apoptosis and autophagy. Since gamma-tocotrienol inhibits DEGS and decreases de novo ceramide synthesis, elevation of ceramides during prolonged gamma-tocotrienol treatment is likely caused by sphingomeylinase-mediated hydrolysis of sphingomyelin. gamma-Tocotrienol treatment led to a time- and dose-dependent decrease in viability of colon, pancreatic and breast cancer cells, overview Homo sapiens